Skip to content

A clinical study of multi-objective optimization technology for lung volume dose parameters based on IMRT in evaluating the control effect of radiation pneumonia after concurrent chemotherapy/radiotherapy for locally advanced lung cancer

A clinical study of multi-objective optimization technology for lung volume dose parameters based on IMRT in evaluating the control effect of radiation pneumonia after concurrent chemotherapy/radiotherapy for locally advanced lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035079
Enrollment
Unknown
Registered
2020-07-30
Start date
2020-07-31
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Single arm optimization strategy group:Multi objective optimization of IMRT strategy for lung volume and dose parameters

Sponsors

The Fifth Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 75 Years

Inclusion criteria

Inclusion criteria: (1) All patients were diagnosed as primary lung cancer by pathology or cytology, and had clear indications for radiotherapy; (2) ECOG physical performance status (PS) score 0~2 points, aged = 3 months. (6) Patients must meet all the following conditions: white blood cell count between 4,000 and 10,000/mm3; neutrophil count >= 2,000/mm3; platelet count >= 100,000/mm3; hemoglobin >= 11.0g/dL; aspartate aminotransferase (AST) and gluten Alanine aminotransferase (ALT) <= 1.5 times the upper limit of normal; total bilirubin <= 24umol/L and blood creatinine <= 85umol/L.

Exclusion criteria

Exclusion criteria: (1) Have received chest radiotherapy; (2) Those who cannot tolerate radiotherapy or stop radiotherapy for more than 1 week in the middle of radiotherapy; (3) The following serious diseases: uncontrollable infections, severe heart failure and myocardial infarction that have occurred in the past 6 months; (4) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Objective efficacy (lesion size);Incidence and severity of radiation pneumonitis;Local control rate of local lesions;3-year, 5-year OS;

Secondary

MeasureTime frame
laboratory examination (blood routine, liver function, renal function, etc.);Adverse event;

Countries

China

Contacts

Public ContactZibin Liang

Department of Thoracic Oncology, the Cancer Center of the Fifth Affiliated Hospital of Sun Yat-Sen University

Liangzb@mail.sysu.edu.cn+86 13926927919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026